BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

Umoja’s assembly of a three-step platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR T cells within patients to treat solid tumors or hematologic malignancies. Named for a...
BioCentury | Nov 19, 2020
Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12 therapy and highlight the ability of its exosome-based approach to extend retention in the tumor microenvironment. Codiak BioSciences Inc. (NASDAQ:CDAK) uses...
BioCentury | Nov 14, 2020
Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

Among CHMP’s monthly roundup of opinions was an MAA withdrawal for BioMarin’s hemophilia gene therapy linked to EMA concerns about safety and durability — issues that FDA raised in August. EMA said...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

AZ, Amgen rise on asthma dataTezepelumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) met the primary endpoint of a statistically significant reduction in annualized asthma exacerbation...
BioCentury | Nov 7, 2020
Product Development

Amgen’s adaptive solution to lupus

The latest study selected for FDA’s Complex Innovative Trial Designs pilot program aims to address one of the biggest problems in clinical development for systemic lupus erythematosus: translating Phase...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

NIH trial of Lilly-AbCellera COVID-19 mAb stopped for futilityNIH has ended enrollment in the ACTIV-3 trial of bamlanivimab to treat hospitalized COVID-19 patients due to lack of efficacy when combined with Veklury remdesivir from Gilead Sciences...
Items per page:
1 - 10 of 5899